<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="gm1-ganglio" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">gm1-ganglio</book-part-id>
      <title-group>
        <title><italic toggle="yes">GLB1-</italic>Related Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Regier</surname>
            <given-names>Debra S</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Pediatric/Genetics Resident, Children&#x02019;s National Medical Center / National Human Genome Research Institute<break/>National Institutes of Health<break/>Bethesda, Maryland</aff>
          <email>regierds@mail.nih.gov</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tifft</surname>
            <given-names>Cynthia J</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Deputy Clinical Director, National Human Genome Research Institute<break/>National Institutes of Health<break/>Bethesda, Maryland</aff>
          <email>ctifft@nih.gov</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>17</day>
          <month>10</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="cmt-4a" document-type="chapter"><italic toggle="yes">GDAP1</italic>-Related Hereditary Motor and Sensory Neuropathy</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ibm" document-type="chapter">
<italic toggle="yes">GNE</italic>-Related Myopathy</related-object>
      <abstract id="gm1-ganglio.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">GLB1</italic>-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB).</p>
          <p>GM1 gangliosidosis includes phenotypes that range from severe to mild. Type I (infantile) begins before age one year; progressive central nervous system dysfunction leads to spasticity, deafness, blindness, and decerebrate rigidity. Life expectancy is two to three years. Type II can be subdivided into the late-infantile form and juvenile form. Type II, late-infantile form begins between ages one and three years; life expectancy is five to ten years. Type II, juvenile form begins between ages three and ten years with insidious plateauing of motor and cognitive development followed by slow regression. Type II may or may not include skeletal dysplasia. Type III begins in the second to third decade with extrapyramidal signs, gait disturbance, and cardiomyopathy; and can be misidentified as Parkinson disease. Intellectual impairment is common late in the disease; skeletal involvement includes short stature, kyphosis, and scoliosis of varying severity.</p>
          <p>MPS IVB is characterized by skeletal changes, including short stature and skeletal dysplasia. Affected children have no distinctive clinical findings at birth. The severe form is usually apparent between ages one and three years, and the attenuated form in late childhood or adolescence. In addition to skeletal involvement, significant morbidity can result from respiratory compromise, obstructive sleep apnea, valvular heart disease, hearing impairment, corneal clouding, and spinal cord compression. Intellect is normal unless spinal cord compression leads to central nervous system compromise.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">GLB1-</italic>related disorders is suspected in individuals with characteristic clinical, neuroimaging, radiographic, and biochemical findings. The diagnosis is confirmed by either deficiency of &#x003b2;-galactosidase enzyme activity or biallelic pathogenic variants in <italic toggle="yes">GLB1</italic>.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Best provided by specialists in biochemical genetics, cardiology, orthopedics, and neurology and therapists knowledgeable about <italic toggle="yes">GLB1-</italic>related disorders; surgery is best performed in centers with surgeons and anesthesiologists experienced in the care of individuals with lysosomal storage disorders; occupational therapy to optimize activities of daily living (including adaptive equipment) and physical therapy to optimize gait and mobility (including orthotics and bracing); early and ongoing interventions to optimize educational and social outcomes.</p>
          <p>For those with GM1 gangliosidosis: Adequate nutrition to maintain growth; speech therapy to optimize oral motor skills; aggressive seizure control; routine management of risk of aspiration, risk of chronic urinary tract infection, and cardiac involvement; when disease is advanced: hospice services for supportive in-home care.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Anesthetic precautions to anticipate and manage complications relating to skeletal involvement and airway compromise; routine immunization; bacterial endocarditis prophylaxis in those with cardiac valvular disease.</p>
          <p>
            <italic toggle="yes">Surveillance:</italic>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>GM1 gangliosidosis: Routine monitoring of growth and nutrition. Assess yearly: quality of life including history and physical examination; seizure risk by a neurologist; cervical spine stability; and hip dislocation risk. Perform every one to three years: electrocardiogram and echocardiogram; eye examination.</p>
            </list-item>
            <list-item>
              <p>MPS IVB: Yearly: perform endurance tests to evaluate functional status of the cardiovascular, pulmonary, musculoskeletal, and nervous systems; assess lower extremities for malalignment, hips for dysplasia/subluxation, thoracolumbar spine for kyphosis, and cervical spine for instability; perform eye examination and audiogram. Perform electrocardiogram and echocardiogram every one to three years depending on disease course; assess for obstructive sleep apnea and restrictive lung disease; monitor nutritional status using MPS IVA-specific growth charts.</p>
            </list-item>
          </list>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Psychotropic medications because of the risk of worsening neurologic disease; obesity in those with skeletal dysplasia</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">GLB1-</italic>related disorders are inherited in an autosomal recessive manner. Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="gm1-ganglio.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="gm1-ganglio.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_gm1-ganglio.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">GLB1</italic>-Related Disorders: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_gm1-ganglio.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>GM1 gangliosidosis</p></list-item><list-item><p>Mucopolysaccharidosis type IVB</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="gm1-ganglio.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="gm1-ganglio.Diagnosis">
        <title>Diagnosis</title>
        <p><italic toggle="yes">GLB1</italic>-related disorders comprise two phenotypically unique disorders, GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB).</p>
        <p>Formal diagnostic criteria have not been established for <italic toggle="yes">GLB1-</italic>related disorders.</p>
        <p>Since MPS IVB is clinically indistinguishable from MPS IVA, it may be appropriate to use the recently published MPS IVA clinical diagnostic criteria as an aid in MPS IVB diagnosis [<xref ref-type="bibr" rid="gm1-ganglio.REF.wood.2013.293">Wood et al 2013</xref>].</p>
        <sec id="gm1-ganglio.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><bold>The diagnosis of <italic toggle="yes">GLB1-</italic>related disorders is suspected</bold> in individuals with the clinical, neuroimaging, radiographic, and biochemical findings summarized by phenotype in <xref ref-type="table" rid="gm1-ganglio.T.clinical_skeletal_neuroima">Table 1</xref>.</p>
          <table-wrap id="gm1-ganglio.T.clinical_skeletal_neuroima" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Clinical, Skeletal, Neuroimaging, and Biochemical Findings in <italic toggle="yes">GLB1-</italic>Related Disorders</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1" rowspan="3" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1">Finding</th>
                  <th id="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2" valign="middle" colspan="4" align="left" scope="colgroup" rowspan="1">GM1 Gangliosidosis</th>
                  <th id="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3" rowspan="3" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3">MPS IVB</th>
                </tr>
                <tr>
                  <th headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2" id="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Type I</th>
                  <th headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2" id="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Type II</th>
                  <th headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2" id="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Type III</th>
                </tr>
                <tr>
                  <th headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1" id="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Infantile</th>
                  <th headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2" id="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Late Infantile</th>
                  <th headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2" id="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Juvenile</th>
                  <th headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3" id="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Chronic/Adult</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Onset of symptoms</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;1 year</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">1-3 years</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">3-10 years</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">10+ years</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">3-5 years</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Eye findings</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">CRS</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">CC</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">CC</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013; CC</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">CC</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Motor abnormalities</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">Extrapyramidal</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 1</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hepatosplenomegaly</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cardiac involvement</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Coarse facial features</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 1</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Skeletal findings</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Neuroimaging</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">PA</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">PA</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">PA</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">+/&#x02013; mild atrophy</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 1</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Urine glycosaminoglycans (GAG)</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_1 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_2 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_2_3 hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2</td>
                  <td headers="hd_h_gm1-ganglio.T.clinical_skeletal_neuroima_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Keratan sulfate&#x000a0;<sup>3</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gm1-ganglio.TF.1.1">
                <label>+ </label>
                <p>= positive finding</p>
              </fn>
              <fn>
                <p>&#x02013; = negative finding</p>
              </fn>
              <fn id="gm1-ganglio.TF.1.1_1">
                <label>+</label>
                <p>/ &#x02013; = variable finding in patient population</p>
              </fn>
              <fn>
                <p>CRS = cherry red spot</p>
              </fn>
              <fn>
                <p>CC = corneal clouding</p>
              </fn>
              <fn>
                <p>PA = progressive atrophy</p>
              </fn>
              <fn id="gm1-ganglio.TF.1.2">
                <label>1. </label>
                <p>Secondary to bony changes</p>
              </fn>
              <fn id="gm1-ganglio.TF.1.3">
                <label>2. </label>
                <p>Oligosaccharide with terminal galactose sugar</p>
              </fn>
              <fn id="gm1-ganglio.TF.1.4">
                <label>3. </label>
                <p>False negative results can be observed.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <sec id="gm1-ganglio.Clinical_Findings">
            <title>Clinical Findings</title>
            <p>
              <bold>GM1 gangliosidosis</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Type I</bold> (infantile; onset age &#x0003c;1 year) is the most common phenotype. Infants have macular cherry-red spots, developmental delay followed by regression generally observed by age six months, hepatosplenomegaly, cardiac involvement, coarse facial features, and generalized skeletal dysplasia of varying severity.</p>
              </list-item>
              <list-item>
                <p><bold>Type II</bold> includes:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Late infantile (onset age 1-3 years). These children typically have corneal clouding (<xref ref-type="fig" rid="gm1-ganglio.F1">Figure 1</xref>), motor abnormalities, and progressive and diffuse atrophy on brain imaging; they may have hepatosplenomegaly, cardiac involvement, and/or skeletal abnormalities.</p>
                  </list-item>
                  <list-item>
                    <p>Juvenile (onset age 3-10 years). These children typically have motor regression and consistent brain MRI findings of progressive atrophy. Overall, the disease progression is slower than in the late-infantile type.</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p><bold>Type III</bold> (chronic/adult) is the mildest form of the disease spectrum with dystonia leading to gait or speech difficulty as the first symptom.</p>
              </list-item>
            </list>
            <p><bold>Mucopolysaccharidosis type IVB (MPS IVB)</bold> is characterized by corneal clouding, cardiac involvement, severe skeletal abnormalities, and short stature [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>]. Developmental milestones, cognitive function, and neurologic function are normal unless neurologic complications (e.g., spinal cord impingement) develop secondary to severe skeletal dysplasia [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.tomatsu.2011.931">Tomatsu et al 2011</xref>].</p>
          </sec>
          <sec id="gm1-ganglio.Radiographic_Findings">
            <title>Radiographic Findings</title>
            <p><bold>GM1 gangliosidosis</bold> (<xref ref-type="fig" rid="gm1-ganglio.F2">Figure 2</xref>)</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Type I and type II.</bold> Findings observed in many, but not all, persons include: dysostosis multiplex with thickened calvaria, J-shaped enlarged sella turcica, hypoplastic/anteriorly beaked thoracolumbar vertebrae, wide spatula-shaped ribs, flared ilia, acetabular dysplasia with flat femoral heads, shortened long bones with diaphyseal widening, pectus carinatum, and/or wide wedge-shaped metacarpals [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Type III.</bold> Only mild vertebral changes may be observed.</p>
              </list-item>
            </list>
            <p><bold>MPS IVB.</bold> See Note. Findings on skeletal survey that suggest the diagnosis of MPS IVB include the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Odontoid hypoplasia with subsequent risk for cervical instability</p>
              </list-item>
              <list-item>
                <p>Kyphosis (curving of the spine that causes a bowing or rounding of the back, which leads to a hunchback or slouching posture)</p>
              </list-item>
              <list-item>
                <p>Gibbus (structural kyphosis due to wedging of one or more adjacent vertebrae)</p>
              </list-item>
              <list-item>
                <p>Scoliosis</p>
              </list-item>
              <list-item>
                <p>Pectus carinatum or excavatum</p>
              </list-item>
            </list>
            <p>Note: (1) Based on wide variations and subtleties of the radiographic findings in MPS IV, multiple body regions should be evaluated. (2) While the radiographic findings in MPS IVA (caused by biallelic <italic toggle="yes">GALNS</italic> pathogenic variants) and MPS IVB are extensive and can be diagnostic, they cannot distinguish MPS IVA from MPS IVB. (See <related-object link-type="booklink" source-id="gene" document-id="mps4a" document-type="chapter">Mucopolysaccharidosis Type IVA</related-object> for a detailed discussion of the radiographic findings.)</p>
          </sec>
          <sec id="gm1-ganglio.Neuroimaging">
            <title>Neuroimaging</title>
            <p><bold>GM1 gangliosidosis.</bold> Brain MRI can show the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Diffuse atrophy and white matter abnormalities</p>
              </list-item>
              <list-item>
                <p>T<sub>2</sub>-weighted hypointensity in the basal ganglia/globus pallidus that is not specific (<xref ref-type="fig" rid="gm1-ganglio.F3">Figure 3</xref>).</p>
              </list-item>
              <list-item>
                <p>In individuals with adult-onset disease: hyperintensity in the putamen and/or mild cerebral atrophy [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.erol.2006.245">Erol et al 2006</xref>, <xref ref-type="bibr" rid="gm1-ganglio.REF.steenweg.2010.2971">Steenweg et al 2010</xref>]</p>
              </list-item>
            </list>
            <p>Brain MR spectroscopy (MRS) has shown patient-specific changes documented in case reports [<xref ref-type="bibr" rid="gm1-ganglio.REF.erol.2006.245">Erol et al 2006</xref>].</p>
          </sec>
          <sec id="gm1-ganglio.Urine_Glycosaminoglycans_GAG">
            <title>Urine Glycosaminoglycans (GAG) Analysis</title>
            <p><bold>GM1 gangliosidosis.</bold> Although a specific GAG pattern in urine is noted in persons with GM1 gangliosidosis, enzyme activity or molecular genetic testing is necessary for diagnosis [<xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>].</p>
            <p><bold>MPS IVB.</bold> Excretion of keratan sulfate in the urine can be diagnostic of MPS IV; however, the presence of keratan sulfate in the urine does not distinguish MPS IVA from MPS IVB; thus, additional studies are warranted (see <xref ref-type="sec" rid="gm1-ganglio.To_ConfirmEstablish_the_Diag">To Confirm/Establish the Diagnosis in a Proband</xref>).</p>
            <p>A glycosaminoglycan screen can be falsely negative; thus, testing to confirm the diagnosis should be performed if there is clinical suspicion (see <xref ref-type="sec" rid="gm1-ganglio.To_ConfirmEstablish_the_Diag">To Confirm/Establish the Diagnosis in a Proband</xref>).</p>
          </sec>
        </sec>
        <sec id="gm1-ganglio.To_ConfirmEstablish_the_Diag">
          <title>To Confirm/Establish the Diagnosis in a Proband</title>
          <p>The diagnosis of a <italic toggle="yes">GLB1-</italic>related disorder in a proband relies on either &#x003b2;-galactosidase enzyme analysis or <italic toggle="yes">GLB1</italic> molecular genetic testing. Despite the availability of molecular genetic testing, the mainstay of diagnosis of <italic toggle="yes">GLB1-</italic>related disorders will likely continue to be enzyme activity because of cost and difficulty in interpreting variants of unknown significance.</p>
          <p><bold>&#x003b2;-galactosidase enzyme analysis.</bold> The definitive diagnosis of a <italic toggle="yes">GLB1-</italic>related disorder can be made by measuring &#x003b2;-galactosidase enzyme activity in peripheral blood leukocytes or fibroblasts.</p>
          <p>The diagnosis of MPS IVB can be confirmed by the combination of keratan sulfate in the urine and decreased enzyme activity for &#x003b2;-galactosidase enzyme activity in peripheral blood leukocytes or fibroblasts in the absence of intellectual disability.</p>
          <table-wrap id="gm1-ganglio.T._galactosidase_enzyme_acti" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>&#x003b2;-Galactosidase Enzyme Activity in <italic toggle="yes">GLB1-</italic>Related Disorders by Phenotype</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_1" rowspan="3" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_1"/>
                  <th id="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2" valign="middle" colspan="4" align="left" scope="colgroup" rowspan="1">GM1 Gangliosidosis</th>
                  <th id="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_3" rowspan="3" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_3">MPS IVB</th>
                </tr>
                <tr>
                  <th headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2" id="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Type I</th>
                  <th headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2" id="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_2" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Type II</th>
                  <th headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2" id="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Type III</th>
                </tr>
                <tr>
                  <th headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_1" id="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_3_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Infantile</th>
                  <th headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_2" id="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_3_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Late Infantile</th>
                  <th headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_2" id="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_3_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Juvenile</th>
                  <th headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_3" id="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_3_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Chronic/Adult</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>&#x003b2;-galactosidase<break/>enzyme activity&#x000a0;<sup>1,&#x000a0;2</sup></bold>
                  </td>
                  <td headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_1 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">Negligible</td>
                  <td headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_2 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">~1%-5%</td>
                  <td headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_2 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">~3%-10%</td>
                  <td headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_2 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_2_3 hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">5%-10%</td>
                  <td headers="hd_h_gm1-ganglio.T._galactosidase_enzyme_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">2%-12%&#x000a0;<sup>3</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gm1-ganglio.TF.2.1">
                <label>1. </label>
                <p>Relative values (% of normal activity)</p>
              </fn>
              <fn id="gm1-ganglio.TF.2.2">
                <label>2. </label>
                <p>Although the percent of residual enzyme activity correlates generally with phenotype, it cannot predict the type of GM1 gangliosidosis. The lack of direct correlation between enzyme activity and disease severity may be due to the use of artificial substrates in the in vitro enzyme assay, which may not exactly replicate in vivo enzyme activity with natural substrates. Modifier genes could theoretically alter enzyme activity and, thus, disease severity.</p>
              </fn>
              <fn id="gm1-ganglio.TF.2.3">
                <label>3. </label>
                <p>
                  <xref ref-type="bibr" rid="gm1-ganglio.REF.santamaria.2007.273">Santamaria et al [2007]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Note: Enzyme activity may not be predictive of carrier status in family members of individuals with a <italic toggle="yes">GLB1-</italic>related disorder.</p>
          <p><bold>Molecular genetic testing.</bold> The definitive diagnosis of a <italic toggle="yes">GLB1-</italic>related disorder can be made by identification of biallelic pathogenic variants in <italic toggle="yes">GLB1</italic> if enzyme analysis is not available and/or results are not definitive (see <xref ref-type="table" rid="gm1-ganglio.T.summary_of_molecular_genet">Table 3</xref>).</p>
          <table-wrap id="gm1-ganglio.T.summary_of_molecular_genet" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">GLB1-</italic>Related Disorders</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Detected&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">GLB1</italic>
                  </td>
                  <td headers="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  <td headers="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;99%&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon or whole-gene deletions</td>
                  <td headers="hd_h_gm1-ganglio.T.summary_of_molecular_genet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;1%&#x000a0;<sup>7</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gm1-ganglio.TF.3.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="gm1-ganglio" object-id="gm1-ganglio.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="gm1-ganglio.TF.3.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="gm1-ganglio.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="gm1-ganglio.TF.3.3">
                <label>3. </label>
                <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
              </fn>
              <fn id="gm1-ganglio.TF.3.4">
                <label>4. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="gm1-ganglio.TF.3.5">
                <label>5. </label>
                <p><xref ref-type="bibr" rid="gm1-ganglio.REF.santamaria.2007.273">Santamaria et al [2007]</xref>, <xref ref-type="bibr" rid="gm1-ganglio.REF.brunettipierri.2008.391">Brunetti-Pierri &#x00026; Scaglia [2008]</xref></p>
              </fn>
              <fn id="gm1-ganglio.TF.3.6">
                <label>6. </label>
                <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="gm1-ganglio.TF.3.7">
                <label>7. </label>
                <p>One individual had a deletion of exon 5 [<xref ref-type="bibr" rid="gm1-ganglio.REF.santamaria.2007.273">Santamaria et al 2007</xref>]. See <xref ref-type="sec" rid="gm1-ganglio.Molecular_Genetics">Molecular Genetics</xref>.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="gm1-ganglio.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="gm1-ganglio.Clinical_Description">
          <title>Clinical Description</title>
          <p><italic toggle="yes">GLB1-</italic>related disorders comprise two phenotypically distinct disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB).</p>
          <sec id="gm1-ganglio.GM1_Gangliosidosis">
            <title>GM1 Gangliosidosis</title>
            <p>The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late infantile and juvenile) to mild (chronic/ adult). Although classification into these types is arbitrary, it is helpful in understanding the variation observed in the timing of disease onset, symptoms, rate of progression, and longevity.</p>
            <p>No prospective natural history studies have been published for GM1 gangliosidosis; however, several case series have been published [<xref ref-type="bibr" rid="gm1-ganglio.REF.hofer.2010.236">Hofer et al 2010</xref>, <xref ref-type="bibr" rid="gm1-ganglio.REF.caciotti.2011.782">Caciotti et al 2011</xref>], as has extensive documentation of more than 200 affected individuals [<xref ref-type="bibr" rid="gm1-ganglio.REF.brunettipierri.2008.391">Brunetti-Pierri &#x00026; Scaglia 2008</xref>].</p>
            <p><bold>Type I (infantile) GM1 gangliosidosis.</bold> Onset of symptoms is prior to age 12 months. In some infants prenatal manifestations include hydrops fetalis (6%) and intrauterine growth retardation (1%) [<xref ref-type="bibr" rid="gm1-ganglio.REF.brunettipierri.2008.391">Brunetti-Pierri &#x00026; Scaglia 2008</xref>].</p>
            <p>The primary findings are severe central nervous system dysfunction [<xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>] manifest as early developmental delay with hypotonia and an exaggerated startle response, followed by spasticity and rapid regression. By the end of the first year, most infants are blind and deaf with severe central nervous system dysfunction leading to decerebrate rigidity [<xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>].</p>
            <p>Cardiomyopathy and seizures are common. Some infants manifest hepatosplenomegaly and poor feeding.</p>
            <p>Other findings include a coarsened facial appearance (often including frontal bossing, depressed nasal bridge with a broad nasal tip, long philtrum), large low-set ears, gingival hypertrophy with macroglossia, coarse thickened skin, and hirsutism.</p>
            <p>Skeletal dysplasia can be seen at the time of diagnosis and may become clinically important over time.</p>
            <p>Disease progression is rapid with blindness often by age one year and death by age two to three years frequently secondary to aspiration pneumonia.</p>
            <p>
              <bold>Type II (late infantile and juvenile) GM1 gangliosidosis</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>The onset of the late infantile form is typically between ages one and three years with life expectancy until ages five to ten years.</p>
              </list-item>
              <list-item>
                <p>The onset of the juvenile form is typically between ages three and ten years and often initially manifests in a school-age child as inability to achieve expected milestones. Disease progression is notable for plateauing of motor and cognitive development followed by slow regression of skills. The juvenile form may or may not have skeletal dysplasia. Life expectancy is well into the second decade.</p>
              </list-item>
            </list>
            <p><bold>Chronic/adult GM1 gangliosidosis</bold> has been best characterized in the Japanese population. Onset of symptoms is in late childhood to the third decade [<xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>], typically presenting with generalized dystonia leading to unsteady gait and speech disturbance. However, within a short period of time, most (64%) have extrapyramidal signs including akinetic-rigid parkinsonism. The symptom cluster is similar to the extrapyramidal signs in Parkinson disease, which is a common misdiagnosis [<xref ref-type="bibr" rid="gm1-ganglio.REF.roze.2005.1366">Roze et al 2005</xref>]. Other common findings are: gait disturbance (44%), cardiomyopathy (38%), speech difficulties (33%), and dystonia (22%) [<xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>].</p>
            <p>Although intellectual impairment is common in late stages of the disease, it may be only mild at time of initial diagnosis.</p>
            <p>Skeletal abnormalities, found in 95% of individuals, are most commonly short stature, kyphosis, and scoliosis of varying severity.</p>
            <p>Prognosis is directly related to the degree of neurologic impairment. Most affected individuals have a shortened life span compared to their unaffected relatives [<xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>].</p>
            <p><bold>Neuropathology</bold>. All individuals with GM1 gangliosidosis have post-mortem neural changes; specifically, meganeurites and ectopic dendritogenesis have been observed. The extent of ganglioside deposition correlates with age of onset and rate of disease progression [<xref ref-type="bibr" rid="gm1-ganglio.REF.steenweg.2010.2971">Steenweg et al 2010</xref>].</p>
          </sec>
          <sec id="gm1-ganglio.Mucopolysaccharidosis_Type_I">
            <title>Mucopolysaccharidosis Type IVB</title>
            <p>MPS IVB is clinically indistinguishable from <related-object link-type="booklink" source-id="gene" document-id="mps4a" document-type="chapter">MPS IVA</related-object>. Prior to the availability of molecular testing, natural history studies of MPS IV included both MPS IVA (&#x0003e;95% of affected individuals) and MPS IVB (&#x0003c;5% of affected individuals). The following information is relevant to both MPS IVA and MPS IVB.</p>
            <p>MPS IV is characterized by corneal clouding, cardiac valvular disease, and skeletal abnormalities, including short stature. In general, neurologic function is normal. Affected children have no distinctive clinical findings at birth. The severe form is usually apparent between ages one and three years. The attenuated form may not become evident until late childhood or adolescence [<xref ref-type="bibr" rid="gm1-ganglio.REF.monta_o.2007.165">Monta&#x000f1;o et al 2007</xref>].</p>
            <p>The initial presentation in both severe and attenuated MPS IV can vary. Kyphoscoliosis, knocked knees (genu valgum), and pectus carinatum are the most common initial manifestations of the severe form [<xref ref-type="bibr" rid="gm1-ganglio.REF.monta_o.2007.165">Monta&#x000f1;o et al 2007</xref>]. In contrast, hip problems including pain, stiffness, and Legg-Perthes disease are common initial manifestations of the attenuated form [<xref ref-type="bibr" rid="gm1-ganglio.REF.hecht.1984.369">Hecht et al 1984</xref>, <xref ref-type="bibr" rid="gm1-ganglio.REF.wraith.1995.263">Wraith 1995</xref>].</p>
            <p>While the skeletal changes in MPS IV are the hallmark findings, involvement of other organ systems can lead to significant morbidity, including respiratory compromise, obstructive sleep apnea, valvular heart disease, hearing impairment, corneal clouding, dental abnormalities, and hepatomegaly.</p>
            <p>Spinal cord compression can result in neurologic compromise, especially in persons with severe disease or delayed diagnosis [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.neufeld.2001">Neufeld &#x00026; Muenzer 2001</xref>, <xref ref-type="bibr" rid="gm1-ganglio.REF.tomatsu.2011.931">Tomatsu et al 2011</xref>].</p>
            <p>Coarse facial features can develop later in life, but the changes are milder than those observed in other mucopolysaccharidoses (see <xref ref-type="sec" rid="gm1-ganglio.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
            <p>Children with MPS IV typically have normal intellectual ability. Ligamentous laxity and joint hypermobility are distinctive features of MPS IV, and are rare among storage disorders.</p>
          </sec>
        </sec>
        <sec id="gm1-ganglio.Pathophysiology">
          <title>Pathophysiology</title>
          <p>GM1 gangliosidosis is caused by pathogenic variants in <italic toggle="yes">GLB1</italic> leading to decreased activity of &#x003b2;-galactosidase, a lysosomal enzyme involved in the metabolism of the sphingolipid GM1 ganglioside. When enzyme activity is decreased, sphingolipid intermediates accumulate in the lysosome and, thus, interfere with appropriate functioning of the organelle. A hallmark of GM1 gangliosidosis is degeneration of the CNS where ganglioside synthesis is the highest.</p>
          <p><italic toggle="yes">GLB1</italic> pathogenic variants leading to MPS IVB result in the accumulation of keratan sulfate, the suspected causative agent for the bone findings in MPS IVB. Note: In MPS IVA (caused by biallelic <italic toggle="yes">GALNS</italic> pathogenic variants) and MPS IVB (caused by biallelic <italic toggle="yes">GLB1</italic> pathogenic variants), keratan sulfate accumulation is thought to be the cause of severe skeletal abnormalities.</p>
        </sec>
        <sec id="gm1-ganglio.GenotypePhenotype_Correlatio">
          <title>Genotype-Phenotype Correlations</title>
          <p><bold>GM1 gangliosidosis</bold>. More than 150 <italic toggle="yes">GLB1</italic> pathogenic variants have been found in GM1 gangliosidosis. Common variants have been identified for each subtype; however, since the vast majority of affected individuals are compound heterozygotes, the same pathogenic variants have been identified in more than one phenotype [<xref ref-type="bibr" rid="gm1-ganglio.REF.santamaria.2007.273">Santamaria et al 2007</xref>; <xref ref-type="bibr" rid="gm1-ganglio.REF.caciotti.2011.782">Caciotti et al 2011</xref>; Author, unpublished results], making phenotype/genotype correlation difficult [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.higaki.2011.843">Higaki et al 2011</xref>].</p>
          <p>Current structure/enzyme activity studies indicate that GM1 gangliosidosis is caused by <italic toggle="yes">GLB1</italic> pathogenic variants that result in impaired function of the &#x003b2;-galactosidase enzyme towards its high affinity substrate, the glycosphingolipid GM1 ganglioside. In contrast, specific <italic toggle="yes">GLB1</italic> variants that cause MPS IVB are proposed to affect the catabolism of keratan sulfate but have little effect on GM1 gangliosides [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>].</p>
          <p><bold>Mucopolysaccharidosis type IVB.</bold> Unique pathogenic variants have been found in MPS IVB. Based on the crystal structure, most of these variants map to the surface or protein core of the enzyme [<xref ref-type="bibr" rid="gm1-ganglio.REF.ohto.2012.1801">Ohto et al 2012</xref>], likely stabilizing the secondary, tertiary, and/or quaternary structure. However, two MPS IVB common variants are located in the ligand binding pocket.</p>
        </sec>
        <sec id="gm1-ganglio.Nomenclature">
          <title>Nomenclature</title>
          <p>In the past GM1 gangliosidosis was referred to as beta-galactosidase-1 deficiency or beta-galactosidosis; mucopolysaccharidosis type IVB was referred to as Morquio syndrome type B. These terms should be used when searching for older literature on GM1 gangliosidosis.</p>
        </sec>
        <sec id="gm1-ganglio.Prevalence">
          <title>Prevalence</title>
          <p><bold>GM1 gangliosidosis</bold> of all types is estimated to occur in one in 100,000 to 300,000 [<xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>]. The most common is the infantile form. The prevalence in Brazil (1:17,000), in persons of Roma ancestry (1:10,000), and in the Maltese Islands (1:3,700) is much higher than in other areas and likely represents founder effects [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.brunettipierri.2008.391">Brunetti-Pierri &#x00026; Scaglia 2008</xref>].</p>
          <p>The prevalence of chronic/adult GM1 gangliosidosis is higher in the Japanese population, likely due both to a founder effect and possibly a greater awareness of the disorder among Japanese healthcare providers [<xref ref-type="bibr" rid="gm1-ganglio.REF.higaki.2011.843">Higaki et al 2011</xref>].</p>
          <p><bold>MPS IVB.</bold> Prior to 1980, MPS IVA and IVB were indistinguishable. The overall prevalence of MPS IV was reported as 1:75,000 to 1:640,000 [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.ohto.2012.1801">Ohto et al 2012</xref>]. Subsequently the prevalence of MPS IVB has been reported as 1:250,000-1:1,000,000 [<xref ref-type="bibr" rid="gm1-ganglio.REF.baehner.2005.1011">Baehner et al 2005</xref>, <xref ref-type="bibr" rid="gm1-ganglio.REF.enns.2009">Enns et al 2009</xref>].</p>
        </sec>
      </sec>
      <sec id="gm1-ganglio.Genetically_Related_Allelic">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those described in this <italic toggle="yes">GeneReview</italic> are associated with mutation of <italic toggle="yes">GLB1</italic>.</p>
      </sec>
      <sec id="gm1-ganglio.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Disorders to consider in the differential diagnosis of the <italic toggle="yes">GLB1-</italic>related disorders include the following.</p>
        <sec id="gm1-ganglio.MPS_IVB">
          <title>MPS IVB</title>
          <p><related-object link-type="booklink" source-id="gene" document-id="mps4a" document-type="chapter"><bold>Mucopolysaccharidosis IVA</bold></related-object>
<bold>(MPS IVA)</bold> and MPS IVB are clinically indistinguishable. Of individuals with the MPS IV phenotype, MPS IVA accounts for more than 95% of affected individuals and MPS IVB accounts for fewer than 5% of affected individuals. The diagnosis of MPS IVA is confirmed by detection either of deficient N-acetylgalactosamine 6-sulfatase (GALNS) enzyme activity or of biallelic <italic toggle="yes">GALNS</italic> pathogenic variants.</p>
        </sec>
        <sec id="gm1-ganglio.GM1_Gangliosidosis_1">
          <title>GM1 Gangliosidosis</title>
          <p><bold>GM2 gangliosidosis</bold> (also known as <related-object link-type="booklink" source-id="gene" document-id="tay-sachs" document-type="chapter">hexosaminidase A deficiency</related-object>) also presents similarly with a range of severity, including infantile, juvenile, and adult forms. Onset of CNS symptoms in GM1 and GM2 gangliosidosis is similar between each of the forms. The infantile forms of both disorders feature cherry red maculae. However, individuals with GM2 gangliosidosis do not have skeletal changes or other non-CNS findings.</p>
          <p><bold>Galactosialidosis</bold> and <bold>sialidosis</bold> (<bold>mucolipidosis I</bold>) need to be considered in the differential diagnosis of GM1 gangliosidosis. Galactosialidosis and sialidosis are caused by deficiencies in enzymes that form a complex with &#x003b2;-galactosidase. This high molecular-weight complex includes &#x003b2;-galactosidase (GM1 gangliosidosis), cathepsin A encoded by <italic toggle="yes">CTSA</italic> (galactosialidosis), and neuramidase 1 encoded by <italic toggle="yes">NEU1</italic> (sialidosis/mucolipidosis I). Note that in galactosialidosis the activities of the enzymes &#x003b2;-galactosidase and neuramidase 1 are reduced, respectively, to about 15% and less than 1% of normal values secondary to a primary deficiency of the protective protein/cathepsin A. Therefore, the activities of cathepsin A and neuraminidase 1 in fibroblasts should be measured to definitively rule out galactosialidosis in an individual with partial deficiency of &#x003b2;-galactosidase.</p>
          <p><bold>Galactosialidosis.</bold> Three forms are distinguished by the age of onset and disease course.</p>
          <list list-type="bullet">
            <list-item>
              <p>Early-infantile galactosialidosis is associated with hydrops fetalis, inguinal hernia, growth abnormality, and hepatosplenomegaly. Dysostosis multiplex, coarse facial features, corneal clouding, cardiomegaly, cherry-red spot of the macula, and kidney failure are also common. Angiokeratomas have been observed. Affected infants typically die by age one year.</p>
            </list-item>
            <list-item>
              <p>Late-infantile galactosialidosis is associated with short stature, dysostosis multiplex, cardiac valvulopathy, hepatosplenomegaly, intellectual disability, and coarse facial features. Cherry-red spot of the macula, angiokeratomas, corneal clouding, and hearing loss can be observed. Life expectancy depends on disease severity.</p>
            </list-item>
            <list-item>
              <p>Juvenile/adult galactosialidosis is associated with a variable age of onset (average 16 years, range 1-40 years). Symptoms include ataxia, myoclonus, seizures, corneal clouding, and progressive intellectual disability. Angiokeratomas, spine abnormalities, cherry red spot of the macula, and vision and hearing loss are common. Life expectancy varies. The highest prevalence has been noted in the Japanese population.</p>
            </list-item>
          </list>
          <p><bold>Sialidosis (mucolipidosis I)</bold>. Accumulation of sialylated oligo- and polysaccharides in tissues and body fluids are likely the cause of widespread cellular damage. Two forms determined by the level of neuramidase I enzyme activity have been identified. The features of sialidosis II more closely resemble GM1 gangliosidosis than sialidosis I.</p>
          <list list-type="bullet">
            <list-item>
              <p>Both sialidosis type II and GM1 gangliosidosis have a range of severity from congenital to juvenile onset. All have dysostosis multiplex, cherry red spot of the macula, and intellectual disability.</p>
              <list list-type="bullet">
                <list-item>
                  <p>The congenital form has prenatal onset with ascites or hydrops fetalis.</p>
                </list-item>
                <list-item>
                  <p>The infantile form has onset in the first year of life with hepatosplenomegaly, developmental regression, and coarse facial features. Over time, affected children can have myoclonus, hearing loss, gingival hyperplasia, and abnormal spacing of the dentition. Life expectancy is into childhood or adolescence.</p>
                </list-item>
                <list-item>
                  <p>The juvenile form has onset in late childhood. Coarse facial features, myoclonus, and angiokeratomas are observed. Life expectancy is symptom-dependent with more mildly affected individuals living into adulthood.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Sialidosis type I is also known as cherry-red spot myoclonus syndrome. Onset is in the teens and twenties. Gait disturbances and reduced visual acuity are the most common presenting symptoms. With time, myoclonus, ataxia, and reduced vision worsen, but are not life threatening. Intellect is normal.</p>
            </list-item>
          </list>
          <p><related-object link-type="booklink" source-id="gene" document-id="mps1" document-type="chapter"><bold>Mucopolysaccharidosis type I</bold></related-object>
<bold>(MPS I)</bold>. Dysostosis multiplex and corneal clouding are seen in both MPS I and <italic toggle="yes">GLB1</italic>-related disorders; however, MPS I has more severe dysostosis multiplex, contractures, and prominent hepatosplenomegaly and does not have cherry red spot of the macula.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="hunter" document-type="chapter"><bold>Mucopolysaccharidosis type II</bold></related-object>
<bold>(MPS II).</bold> Children with MPS II have developmental delay and dysostosis multiplex, also seen in the juvenile form of GM1 gangliosidosis. At the time of diagnosis, prominent hepatosplenomegaly, joint contractures, dermal pebbling, clear corneae, and a coarse facial appearance distinguish MPS II from <italic toggle="yes">GLB1</italic>-realated disorders. Furthermore, MPS II, an X-linked disorder, is observed in males only, whereas GM1 gangliosidosis, an autosomal recessive disorder, is observed in males and females.</p>
          <p>
            <bold>Mucolipidoses</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="ml2" document-type="chapter"><bold>Mucolipidosis II</bold></related-object>
<bold>(ML II)</bold> (I-cell disease) includes skeletal dysplasia, global developmental delay, and growth abnormalities similar to GM1 gangliosidosis type I. ML II has more severe and earlier onset skeletal dysplasia than GM1 gangliosidosis. ML II can present prenatally with low birth weight or in the neonatal period with skeletal dysplasia, global development delay, and coarse facial features. In comparison, children with GM1 gangliosidosis can be normal as neonates and present in early infancy.</p>
            </list-item>
            <list-item>
              <p><bold>Mucolipidosis III</bold> (both <related-object link-type="booklink" source-id="gene" document-id="ml3a" document-type="chapter">Mucolipidosis III Alpha/Beta</related-object> and <related-object link-type="booklink" source-id="gene" document-id="ml3c" document-type="chapter">Mucolipidosis III Gamma</related-object>) (pseudo-Hurler polydystrophy) includes onset of clinical features in the preschool years (corneal clouding, cardiac valvular abnormalities, developmental delay, dysostosis multiplex) similar to those observed in the juvenile form of GM1 gangliosidosis. In contrast with GM1 gangliosidosis, ML III usually presents with hand and shoulder arthritis, significant short stature, and/or claw hand deformity.</p>
            </list-item>
          </list>
          <p>The differential diagnosis of chronic/adult GM1 gangliosidosis includes <related-object link-type="booklink" source-id="gene" document-id="parkinson-overview" document-type="chapter">Parkinson disease</related-object>, adult-onset <related-object link-type="booklink" source-id="gene" document-id="sma" document-type="chapter">spinal muscular atrophy</related-object>, <related-object link-type="booklink" source-id="gene" document-id="ataxias" document-type="chapter">spinal cerebellar ataxia</related-object>, <related-object link-type="booklink" source-id="gene" document-id="tay-sachs" document-type="chapter">adult-onset GM2 gangliosidosis</related-object>, juvenile <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Huntington disease</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="wilson" document-type="chapter">Wilson disease</related-object>.</p>
          <p>Note: Positive testing for anti-GM1 ganglioside antibodies is not indicative of a diagnosis of GM1 gangliosidosis. These test results are associated with multifocal motor neuropathy or Guillain-Barr&#x000e9; syndrome [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.kornberg.2000.191">Kornberg 2000</xref>].</p>
        </sec>
      </sec>
      <sec id="gm1-ganglio.Management">
        <title>Management</title>
        <sec id="gm1-ganglio.Evaluations_Following_Initia">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with a <italic toggle="yes">GLB1-</italic>related disorder (GM1 gangliosidosis or MPS IVB), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Developmental history and assessment to document past and current motor and cognitive function, as a baseline in the event of future psychomotor and/or cognitive regression</p>
            </list-item>
            <list-item>
              <p>Physical examination for evidence of hepatosplenomegaly</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic examination, especially for evidence of corneal clouding and cherry red spot of the macula</p>
            </list-item>
            <list-item>
              <p>Evaluation by a pediatric cardiologist (including electrocardiogram and echocardiogram) to assess for cardiac involvement</p>
            </list-item>
            <list-item>
              <p>Skeletal survey to determine the extent of skeletal involvement</p>
            </list-item>
            <list-item>
              <p>Flexion and extension x-rays of the cervical spine to assess for atlanto-axial instability</p>
            </list-item>
            <list-item>
              <p>Electroencephalogram to assess for seizure disorder, if indicated</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation with genetic counseling</p>
            </list-item>
          </list>
        </sec>
        <sec id="gm1-ganglio.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment and quality of life can be optimized when care is provided by specialists in biochemical genetics, cardiology, orthopedics, and neurology, and therapists knowledgeable about <italic toggle="yes">GLB1-</italic>related disorders.</p>
          <list list-type="bullet">
            <list-item>
              <p>Surgery is best performed in centers with surgeons and anesthesiologists experienced in the care of individuals with lysosomal storage disorders.</p>
            </list-item>
            <list-item>
              <p>Occupational therapy to optimize activities of daily living (including adaptive equipment)</p>
            </list-item>
            <list-item>
              <p>Physical therapy to optimize gait, comfort, and mobility including orthotics and bracing to improve mobility and flexibility</p>
            </list-item>
            <list-item>
              <p>Early and ongoing interventions to optimize educational and social outcomes are recommended.</p>
            </list-item>
          </list>
          <p>
            <bold>GM1 gangliosidosis</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>For patients with GM1 gangliosidosis type I or II, physiatry for appropriate mobility interventions, such as strollers and wheelchairs</p>
            </list-item>
            <list-item>
              <p>Speech therapy to optimize oral motor skills and manage aspiration risk</p>
            </list-item>
            <list-item>
              <p>Maintenance of adequate hydration and adequate calories for growth. Consider gastrostomy (G-) tube or naso-gastric (NG) tube placement as needed.</p>
            </list-item>
            <list-item>
              <p>Routine management of secretions and risk of aspiration with attention to risk for pulmonary sequelae</p>
            </list-item>
            <list-item>
              <p>Routine management of chronic urinary tract infections secondary to incontinence and chronic dehydration</p>
            </list-item>
            <list-item>
              <p>Aggressive seizure control</p>
            </list-item>
            <list-item>
              <p>Medical management of cardiac involvement</p>
            </list-item>
            <list-item>
              <p>When disease is advanced, provide access to hospice services for supportive in-home care</p>
            </list-item>
          </list>
          <p>
            <bold>MPS IVB</bold>
          </p>
          <p>Since <related-object link-type="booklink" source-id="gene" document-id="mps4a" document-type="chapter">MPS IVA</related-object> and IVB are clinically indistinguishable, details of interventions are based on those recommended for MPS in general or specifically MPS IVA.</p>
        </sec>
        <sec id="gm1-ganglio.Prevention_of_Secondary_Comp">
          <title>Prevention of Secondary Complications</title>
          <p><bold>Immunizations</bold>. All individuals with <italic toggle="yes">GLB1</italic>-related disorders should receive routine immunizations. Influenza and pneumococcal immunizations should be administered on schedule because of the low pulmonary reserve of individuals with MPS IVB and the risk for secondary infections due to chronic disease in children with GM1 gangliosidosis.</p>
          <p><bold>Bacterial endocarditis prophylaxis</bold> is recommended for all high-risk patients, including those with a prosthetic cardiac valve, prosthetic material used for cardiac valve repair, or previous infective endocarditis [<xref ref-type="bibr" rid="gm1-ganglio.REF.wilson.2007.739">Wilson et al 2007</xref>].</p>
          <p><bold>Anesthesia.</bold> Because children with MPS IVB and those with GM1 gangliosidosis with skeletal involvement (spine anomalies, short neck, large head, and atlantoaxial instability) are at increased risk for complications of anesthesia, the following are recommended [<xref ref-type="bibr" rid="gm1-ganglio.REF.walker.2013.211">Walker et al 2013</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Preoperative evaluation should include a history of complications with previous anesthetics, as well as any ongoing problems with airway obstruction, the heart, and respiratory function.</p>
            </list-item>
            <list-item>
              <p>Obtain flexion/extension x-rays of the lateral cervical spine [<xref ref-type="bibr" rid="gm1-ganglio.REF.muhlebach.2011.133">Muhlebach et al 2011</xref>; <xref ref-type="bibr" rid="gm1-ganglio.REF.tomatsu.2011.931">Tomatsu et al 2011</xref>; Author, unpublished observations].</p>
            </list-item>
            <list-item>
              <p>Fiber-optic bronchoscopy and smaller than expected endotracheal tubes are often required [<xref ref-type="bibr" rid="gm1-ganglio.REF.muhlebach.2011.133">Muhlebach et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>For procedures lasting greater than 45 minutes, intraoperative spinal cord monitoring may be necessary to detect exacerbation of pre-existing spinal stenosis.</p>
            </list-item>
            <list-item>
              <p>Post-operative management may be complicated by pre-existing sleep apnea and/or pulmonary edema [<xref ref-type="bibr" rid="gm1-ganglio.REF.morgan.2002.641">Morgan et al 2002</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="gm1-ganglio.Surveillance">
          <title>Surveillance</title>
          <sec id="gm1-ganglio.GM1_Gangliosidosis_2">
            <title>GM1 Gangliosidosis</title>
            <p><bold>Assessment of quality of life</bold> by a physiotherapist; yearly and before/after major medical events</p>
            <p>
              <bold>Musculoskeletal</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Yearly history and physical examination to evaluate for new skeletal abnormalities that might lead to decreased quality of life</p>
              </list-item>
              <list-item>
                <p>Yearly evaluation for cervical spine instability including detailed physical examination and assessment for new neurologic findings, followed by imaging if indicated</p>
              </list-item>
              <list-item>
                <p>Monitoring of hip joint stability re risk of hip dislocation. Obtain straight and frog-leg imaging if there is pain with movement or a change in mobility (which in neurologically compromised patients can present as inability to ambulate, unexplained crying, or pain).</p>
              </list-item>
            </list>
            <p><bold>Cardiac.</bold> Electrocardiogram and echocardiogram every one to three years, if there is a history of cardiac dysfunction and/or new symptoms</p>
            <p><bold>Growth.</bold> Monitoring of growth and nutrition by a nutritionist with knowledge of neurodegenerative or metabolic disease</p>
            <p><bold>Eye.</bold> Evaluation for visual acuity and corneal clouding every 1-3 years</p>
            <p><bold>Seizures.</bold> Yearly evaluation by a neurologist; consideration of EEG if there is an acute change in mental status, a sudden decline in activity/milestones, or abnormal movements</p>
          </sec>
          <sec id="gm1-ganglio.MPS_IVB_1">
            <title>MPS IVB</title>
            <p>Note: The recommendations for <related-object link-type="booklink" source-id="gene" document-id="mps4a" document-type="chapter">MPS IVA</related-object> are appropriate for MPS IVB since MPS IVA and MPS IVB are clinically indistinguishable.</p>
            <p><bold>Assessment of quality of life</bold> by a physiotherapist:</p>
            <list list-type="bullet">
              <list-item>
                <p>Yearly: track progress and optimize ambulation</p>
              </list-item>
              <list-item>
                <p>Yearly, before and after surgical procedures, and as clinically indicated: endurance tests including six-minute walk test (6MWT) and three-minute stair climb test (3MSC) to evaluate functional status of the cardiovascular, pulmonary, musculoskeletal and nervous systems</p>
              </list-item>
            </list>
            <p><bold>Musculoskeletal.</bold> Assessment for the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Lower-extremity misalignment: yearly clinical examinations to assess lower extremity alignment</p>
              </list-item>
              <list-item>
                <p>Hip dysplasia/subluxation: yearly radiographs of the hips, as clinically warranted</p>
              </list-item>
              <list-item>
                <p>Cervical spine instability</p>
              </list-item>
              <list-item>
                <p>Note: <xref ref-type="bibr" rid="gm1-ganglio.REF.solanki.2013.339">Solanki et al [2013]</xref> recommend the following guidelines for monitoring spinal involvement in those with MPS IVA:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Neurologic examination every six months</p>
                  </list-item>
                  <list-item>
                    <p>Plain x-rays of the cervical spine (AP, lateral, neutral, and flexion/extension) every six months</p>
                  </list-item>
                  <list-item>
                    <p>Plain x-rays of the spine (AP and lateral thoracolumbar) every two to three years if there is evidence of kyphosis and/or scoliosis</p>
                  </list-item>
                  <list-item>
                    <p>MRI neutral position: whole spine every year</p>
                  </list-item>
                  <list-item>
                    <p>MRI: flexion/extension of the cervical spine every one to three years</p>
                    <p>These guidelines can be modified as appropriate.</p>
                  </list-item>
                </list>
              </list-item>
            </list>
            <p><bold>Cardiac.</bold> Electrocardiogram and echocardiogram every one to three years depending on disease course [<xref ref-type="bibr" rid="gm1-ganglio.REF.hendriksz.2013.309">Hendriksz et al 2013</xref>]</p>
            <p><bold>Respiratory.</bold> Assessment for the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Obstructive sleep apnea: yearly history focused on sleep patterns and sounds. Evaluation by an otolaryngologist for adenotonsillectomy. Polysomnography if any clinical suspicion exists.</p>
              </list-item>
              <list-item>
                <p>Restrictive lung disease: assessment of pulmonary function when age-appropriate at diagnosis and then yearly. Note: The benefit of non-invasive pulmonary function tests, impulse oscillometry, and thoracoabdominal motion analysis has been demonstrated in children with MPS IV [<xref ref-type="bibr" rid="gm1-ganglio.REF.rodriguez.2010.679">Rodriguez et al 2010</xref>].</p>
              </list-item>
            </list>
            <p><bold>Growth.</bold> Use of MPS IVA-specific growth charts to monitor nutritional status [<xref ref-type="bibr" rid="gm1-ganglio.REF.monta_o.2007.165">Monta&#x000f1;o et al 2007</xref>, <xref ref-type="bibr" rid="gm1-ganglio.REF.monta_o.2008.1286">Monta&#x000f1;o et al 2008</xref>]</p>
            <p>
              <bold>Eye</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Yearly: measurement of visual acuity, refractive error, and intraocular pressure; slit lamp examination of cornea; examination of the posterior segment</p>
              </list-item>
              <list-item>
                <p>For those with rod and cone retinal dystrophy: Retinal examination and electroretinography (ERG) under scotopic and photopic conditions at onset, then every five years [<xref ref-type="bibr" rid="gm1-ganglio.REF.hendriksz.2013.309">Hendriksz et al 2013</xref>]</p>
              </list-item>
            </list>
            <p><bold>Dental.</bold> Evaluation every six months</p>
            <p><bold>Hearing.</bold> Yearly audiogram</p>
          </sec>
        </sec>
        <sec id="gm1-ganglio.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Because psychotropic medications have been associated with worsening neurologic disease in adults with Tay-Sachs disease (which is caused by deficiency of the second enzyme in the &#x003b2;-galactosidase pathway) [<xref ref-type="bibr" rid="gm1-ganglio.REF.shapiro.2006.875">Shapiro et al 2006</xref>], use of these medications in individuals with a <italic toggle="yes">GLB1</italic>-related disorder should be avoided whenever possible [<xref ref-type="bibr" rid="gm1-ganglio.REF.shapiro.2006.875">Shapiro et al 2006</xref>].</p>
          <p>For persons with MPS IVB, excessive weight gain causes undue stress on the axial skeleton and may decrease the ability to ambulate independently. Thus, it is important that nutrition optimize growth while maintaining a lean habitus.</p>
        </sec>
        <sec id="gm1-ganglio.Evaluation_of_Relatives_at_R">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="gm1-ganglio.Related_Genetic_Counseling_I">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="gm1-ganglio.Therapies_Under_Investigatio">
          <title>Therapies Under Investigation</title>
          <p>No FDA-approved treatments for <italic toggle="yes">GLB1-</italic>related disorders exist.</p>
          <p>While there is currently no effective treatment for GM1 gangliosidosis, multiple interventions are promising, based on in vitro studies and animal models.</p>
          <p>Although many lysosomal storage diseases have positive outcomes with hematopoietic stem cell transplantation (HSCT), in one individual with the juvenile form of GM1 gangliosidosis diagnosed prior to onset of symptoms, HSCT did not prevent the development of manifestations. This failure was attributed to the inability of sufficient stem cells to cross the blood-brain barrier rapidly enough to affect lipid accumulation in the central nervous system (CNS) [<xref ref-type="bibr" rid="gm1-ganglio.REF.shield.2005.797">Shield et al 2005</xref>].</p>
          <p>Due to the inability of large molecular-weight enzymes to cross the blood-brain barrier, investigators have been studying small molecules as possible chaperones for partially functioning &#x003b2;-galactosidase in the CNS. These chaperones are thought to stabilize the residual endogenous enzyme and facilitate transport to the lysosome.</p>
          <list list-type="bullet">
            <list-item>
              <p>In an in vitro study using fibroblasts from an affected individual, N-octyl-4-epi-B-valienamine stabilized &#x003b2;-galactosidase, reduced lipid accumulations, and improved lipid trafficking [<xref ref-type="bibr" rid="gm1-ganglio.REF.higaki.2011.843">Higaki et al 2011</xref>]. Furthermore, oral administration of this compound to mice with GM1 gangliosidosis led to increased enzyme activity and reduced substrate levels [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.brunettipierri.2008.391">Brunetti-Pierri &#x00026; Scaglia 2008</xref>].</p>
            </list-item>
            <list-item>
              <p>A second chaperone compound, the imino sugar N-butyl deoxynojirimycin (miglustat), also showed promising outcomes in a murine model of GM1 gangliosidosis [<xref ref-type="bibr" rid="gm1-ganglio.REF.elliotsmith.2008.204">Elliot-Smith et al 2008</xref>]. Miglustat, which is FDA approved for the treatment of <related-object link-type="booklink" source-id="gene" document-id="gaucher" document-type="chapter">Gaucher disease</related-object>, has been used in a few individuals with the juvenile form of GM1 gangliosidosis of whom some showed improvement [Author, unpublished observation].</p>
            </list-item>
            <list-item>
              <p>In addition, other imino sugar derivatives have shown increased enzyme activity, facilitated localization of &#x003b2;-galactosidase to lysosomes in fibroblasts of affected individuals [<xref ref-type="bibr" rid="gm1-ganglio.REF.fantur.2012.495">Fantur et al 2012</xref>], and shown improved enzyme activity in a mouse model of GM1 gangliosidosis [<xref ref-type="bibr" rid="gm1-ganglio.REF.takai.2013.526">Takai et al 2013</xref>].</p>
            </list-item>
          </list>
          <p>Considerable progress has been made in gene therapy in a murine model of GM1 gangliosidosis. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="gm1-ganglio-AnimalModel.pdf" content-type="local-data">animal model</inline-supplementary-material>.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="gm1-ganglio.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="gm1-ganglio.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">GLB1-</italic>related disorders (i.e., GM1 gangliosidosis and MPS IVB) are inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="gm1-ganglio.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one mutated allele).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with a severe <italic toggle="yes">GLB1</italic>-related disorder do not reproduce.</p>
            </list-item>
            <list-item>
              <p>The offspring of an individual with a mild <italic toggle="yes">GLB1</italic>-related disorder are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">GLB1.</italic></p>
              <p>Note: No studies addressing fertility in individuals with a mild <italic toggle="yes">GLB1</italic>-related disorder have been published.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="gm1-ganglio.Carrier_Detection">
          <title>Carrier Detection</title>
          <p><bold>Molecular genetic testing</bold>. Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
          <p><bold>Biochemical genetic testing.</bold> Enzyme activity may not be predictive of carrier status in family members of individuals with a <italic toggle="yes">GLB1-</italic>related disorder.</p>
        </sec>
        <sec id="gm1-ganglio.Related_Genetic_Counseling_I">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="gm1-ganglio.Prenatal_Testing_and_Preimpl">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">GLB1</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for a <italic toggle="yes">GLB1</italic>-related disorder are possible.</p>
        </sec>
      </sec>
      <sec id="gm1-ganglio.Resources">
        <title>Resources</title>
      </sec>
      <sec id="gm1-ganglio.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="gm1-ganglio.Molecular_Genetic_Pathogenes">
          <title>Molecular Genetic Pathogenesis</title>
          <p><italic toggle="yes">GLB1-</italic>related disorders comprise two phenotypically distinct disorders: GM1 gangliosidosis with varying degrees of neurologic involvement and mucopolysaccharidosis type IVB (MPS IVB), a progressive skeletal dysplasia.</p>
          <p>GM1 gangliosidosis results from accumulation of glycoconjugates with a terminal &#x003b2;-galactose as a result of deficiency of the enzyme &#x003b2;-galactosidase. An inverse ratio of enzyme activity and substrate storage has been observed, with the lowest amounts of enzyme activity and highest amounts of storage material noted in neural tissue from individuals with the most severe form: infantile GM1 gangliosidosis.</p>
          <p><italic toggle="yes">GLB1</italic> is conserved among species. GM1 gangliosidosis has been documented in cats, dog, sheep, calves, and mice [<xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>].</p>
          <p><bold>Gene structure.</bold> The longest transcript variant <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000404.2">NM_000404.2</ext-link> has 16 exons spanning more than 60 kb.</p>
          <p>Multiple transcript variants give rise to different isoforms. Two alternatively spliced mRNA variants are a 2.5-kb transcript that encodes the canonical, lysosomal &#x003b2;-galactosidase enzyme precursor and a minor 2.0-kb transcript in which exons 3, 4, and 6 are deleted and exon 5 is translated from a different reading frame [<xref ref-type="bibr" rid="gm1-ganglio.REF.morreau.1989.20655">Morreau et al 1989</xref>]. The alternatively spliced exon 5 encodes a unique 32 amino-acid peptide that contains a tropoelastin-binding domain [<xref ref-type="bibr" rid="gm1-ganglio.REF.privitera.1998.6319">Privitera et al 1998</xref>]. This shorter, catalytically inactive &#x003b2;-galactosidase isoform, named the &#x02018;elastin binding protein&#x02019; (EBP), plays an important role in elastogenesis [<xref ref-type="bibr" rid="gm1-ganglio.REF.privitera.1998.6319">Privitera et al 1998</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="gm1-ganglio" object-id="gm1-ganglio.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic variants.</bold> A deletion of exon 5 secondary to unequal crossover between intronic Alu sequences is the largest reported deletion [<xref ref-type="bibr" rid="gm1-ganglio.REF.santamaria.2007.273">Santamaria et al 2007</xref>].</p>
          <table-wrap id="gm1-ganglio.T.glb1_pathogenic_variants_d" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p><italic toggle="yes">GLB1</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change&#x000a0;<sup>1</sup><break/>(Alias&#x000a0;<sup>2</sup>)</th>
                  <th id="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Ethnicity / Phenotype</th>
                  <th id="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.152T&#x0003e;C</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile51Thr</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Japanese / GM1 adult form</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_4" rowspan="8" valign="middle" align="left" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000404.2">NM_000404.2</ext-link>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000395.2">NP_000395.2</ext-link></td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.601C&#x0003e;T</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg201Cys</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Japanese / GM1 juvenile form</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.602G&#x0003e;A</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg201His</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">MPS IVB, GM1 juvenile form</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.622C&#x0003e;T</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg208Cys</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">American / GM1 infantile form</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.817_818delTGinsCT<break/>(851-852 TG&#x0003e;CT)</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp273Leu</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Northern European origin / MPS IVB</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1445G&#x0003e;A</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg482His</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Italian / GM1 infantile form</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1577_1578dupG&#x000a0;<sup>3</sup><break/>(1622_1627insG)</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp527LeufsTer5&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Brazilian / GM1</td>
                </tr>
                <tr>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.176G&#x0003e;A</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg59His</td>
                  <td headers="hd_h_gm1-ganglio.T.glb1_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Roma, Brazilian / GM1 infantile and juvenile forms</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="gm1-ganglio.TF.4.1">
                <label>1. </label>
                <p>Reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.sperb.2013.113">Sperb et al [2013]</xref>, <xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al [2014]</xref></p>
              </fn>
              <fn id="gm1-ganglio.TF.4.2">
                <label>2. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="gm1-ganglio.TF.4.3">
                <label>3. </label>
                <p>Duplication results in the addition of another G to a series of six G nucleotides.</p>
              </fn>
              <fn id="gm1-ganglio.TF.4.4">
                <label>4. </label>
                <p>"fsTer#" indicates a frameshift beginning at codon 527Leu with the new frame ending in a stop (Ter). The &#x02018;#&#x02019; indicates the position of the stop in the new reading frame, calculated starting at the first changed amino acid that is created by the frame shift, and ending at the first stop codon (fsTer#). The total length of the new shifted frame is 5 (p.Trp527LeufsTer5).</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">GLB1</italic> encodes an 88-kd precursor protein, the 677 amino-acid protein (&#x003b2;-galactosidase) which includes an N-terminal 23 amino-acid signal peptide that allows for lysosome localization. The mature protein is formed by proteolytic cleavage of the C-terminus to make a heterodimer of the cleavage products [<xref ref-type="bibr" rid="gm1-ganglio.REF.van_der_spoel.2000.10035">van der Spoel et al 2000</xref>].</p>
          <p>The crystal structure shows a TIM barrel domain, the functional domain of the glycoside hydrolase activity of the enzyme. Within this domain, the glycosidase activity depends on a pair of carboxylic acids (one as the catalytic nucleophile and the other as the acid/base catalyst). In human &#x003b2;-galactosidase, the carboxylic acids are located in the Glu-268 and Glu-188 residues, in the fourth and seventh strands of the TIM barrel, respectively. For this reason &#x003b2;-galactosidase is a member of the 4/7 superfamily of enzymes.</p>
          <p>Based on crystal structures the protein forms a dimer; some of the pathogenic variants on the surface of the molecule are hypothesized to destabilize this dimerization and thus affect enzymatic activity [<xref ref-type="bibr" rid="gm1-ganglio.REF.ohto.2012.1801">Ohto et al 2012</xref>].</p>
          <p>Multiple studies have demonstrated that &#x003b2;-galactosidase forms a high molecular-weight complex with other two lysosomal enzymes:</p>
          <list list-type="bullet">
            <list-item>
              <p>Lysosomal sialidase neuraminidase 1 (NEU1). Deficiency of NEU1 results in sialidosis (mucolipidosis I). See <xref ref-type="sec" rid="gm1-ganglio.Differential_Diagnosis">Differential Diagnosis</xref>.</p>
            </list-item>
            <list-item>
              <p>Serine carboxypeptidase protective protein/cathepsin A (PPCA) [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.d_azzo.2001">d&#x02019;Azzo et al 2001</xref>, <xref ref-type="bibr" rid="gm1-ganglio.REF.d_azzo.2010.1453">d&#x02019;Azzo &#x00026; Bonten 2010</xref>]. Interaction of &#x003b2;-galactosidase with PPCA is essential for the correct lysosomal compartmentalization of the enzyme and for its intralysosomal stability [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.d_azzo.2010.1453">d&#x02019;Azzo &#x00026; Bonten 2010</xref>]. Deficiency of PPCA results in a secondary deficiency of &#x003b2;-galactosidase, resulting in the disorder galactosialidosis [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.d_azzo.2010.1453">d&#x02019;Azzo &#x00026; Bonten 2010</xref>]. See <xref ref-type="sec" rid="gm1-ganglio.Differential_Diagnosis">Differential Diagnosis</xref>.</p>
            </list-item>
          </list>
          <p>Although the crystal structure of the purified protein did not reveal the surface residues required for interaction with PPCA and NEU1, variants in the surface residues in the quaternary structure of &#x003b2;-galactosidase are pathogenic and, thus, may represent sites of such interaction.</p>
          <p><bold>Abnormal gene product.</bold> The abnormal gene products with pathogenic variants in <italic toggle="yes">GLB1</italic> make &#x003b2;-galactosidase with abnormal function.</p>
          <list list-type="bullet">
            <list-item>
              <p>Single nucleotide variants either directly affect the catalytic domain or result in protein misfolding and subsequent mistargeting or degradation through the endoplasmic reticulum-associated protein degradation pathway.</p>
            </list-item>
            <list-item>
              <p>Variants in amino acid residues at the surface of the protein may be pathogenic due to destabilization of the dimerization of the enzyme, thus altering enzymatic activity [<xref ref-type="bibr" rid="gm1-ganglio.REF.ohto.2012.1801">Ohto et al 2012</xref>].</p>
            </list-item>
          </list>
          <p>Most <italic toggle="yes">GLB1</italic> variants alter the tertiary structure, leading to changes in the ligand-binding pocket. A few variants reside in the ligand-binding pocket [<xref ref-type="bibr" rid="gm1-ganglio.REF.ohto.2012.1801">Ohto et al 2012</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>Changes that alter the overall structure of the TIM barrel domain, responsible for catalysis, are the most detrimental, leading to the infantile form of GM1 gangliosidosis.</p>
            </list-item>
            <list-item>
              <p>In contrast, surface or solvent-exposed pathogenic variants tend to be associated with the juvenile and chronic/adult forms of GM1 gangliosidosis.</p>
              <p>Note: While the study of <xref ref-type="bibr" rid="gm1-ganglio.REF.ohto.2012.1801">Ohto et al [2012]</xref> was instrumental in understanding structure/function relationships of individual pathogenic variants, it offered less insight into the phenotype-genotype correlations in persons with compound heterozygous variants.</p>
            </list-item>
          </list>
          <p>Current structure/enzyme activity studies [reviewed in <xref ref-type="bibr" rid="gm1-ganglio.REF.suzuki.2014">Suzuki et al 2014</xref>] indicate that:</p>
          <list list-type="bullet">
            <list-item>
              <p>GM1 gangliosidosis is caused by pathogenic variants in <italic toggle="yes">GLB1</italic> that impair the activity of &#x003b2;-galactosidase toward its high-affinity substrate, the glycosphingolipid GM1 ganglioside;</p>
            </list-item>
            <list-item>
              <p>MPS IVB is caused by pathogenic variants that impair the catabolism of keratan sulfate, and have little effect on GM1 gangliosides.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="gm1-ganglio.References">
        <title>References</title>
        <sec id="gm1-ganglio.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="gm1-ganglio.Literature_Cited.reflist0">
            <ref id="gm1-ganglio.REF.baehner.2005.1011">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baehner</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmiedeskamp</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krummenauer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miebach</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bajbouj</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whybra</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohlsch&#x000fc;tter</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kampmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Cumulative incidence rates of the mucopolysaccharidoses in Germany.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>28</volume>
                <fpage>1011</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16435194</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.brunettipierri.2008.391">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brunetti-Pierri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaglia</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects.</article-title>
                <source>Mol Genet Metab</source>
                <volume>94</volume>
                <fpage>391</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18524657</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.caciotti.2011.782">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Caciotti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garman</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivera-Colon</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Procopio</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catarzi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferri</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guido</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martelli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parinini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antuzzi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sibilio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontana</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salviati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akinci</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cereda</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionis-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deodato</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d&#x02019;Amico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d&#x02019;Azzo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filocamo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scarpa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tifft</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasperini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasquini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guerrini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donati</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrone</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings.</article-title>
                <source>Biochim Biophys Acta.</source>
                <volume>1812</volume>
                <fpage>782</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">21497194</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.d_azzo.2001">
              <mixed-citation publication-type="book">d&#x02019;Azzo A, Andria G, Strisciuglio P, Galjaard H. Galactosialidosis. In: Scriver C, Beaudet A, Sly W, Valle D, ed. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease.</italic> New York, NY: McGraw-Hill Publishing; 2001:3811-26.</mixed-citation>
            </ref>
            <ref id="gm1-ganglio.REF.d_azzo.2010.1453">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>d&#x02019;Azzo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonten</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Molecular mechanisms of pathogenesis in a glycosphingolipid and a glycoprotein storage disease.</article-title>
                <source>Biochem Soc Trans.</source>
                <year>2010</year>
                <volume>38</volume>
                <fpage>1453</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21118106</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.elliotsmith.2008.204">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elliot-Smith</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speak</surname>
                    <given-names>AO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lloyd-Evans</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Spoel</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeyakumar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butters</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dwek</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d'Azzo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platt</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>94</volume>
                <fpage>204</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">18387328</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.enns.2009">
              <mixed-citation publication-type="book">Enns GM, Steiner RD, Cowan TM. Lysosomal disorders. In: Sarafoglou K, Hoffmann G, Roth K, eds. <italic toggle="yes">Pediatric Endocrinology and Inborn Errors of Metabolism.</italic> McGraw-Hill; 2009:721-55.</mixed-citation>
            </ref>
            <ref id="gm1-ganglio.REF.erol.2006.245">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Erol</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alehan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pourbagher</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canan</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vefa Yildirim</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Neuroimaging findings in infantile GM1 gangliosidosis.</article-title>
                <source>Eur J Paediatr Neurol.</source>
                <volume>10</volume>
                <fpage>245</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17052929</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.fantur.2012.495">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fantur</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wrodnigg</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000fc;tz</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pabst</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB1 alleles causing GM1-gangliosidosis and Morquio B disease.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>35</volume>
                <fpage>495</fpage>
                <lpage>503</lpage>
                <pub-id pub-id-type="pmid">22033734</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.hecht.1984.369">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hecht</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>CI</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>TK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <article-title>Mild manifestations of the Morquio syndrome.</article-title>
                <source>Am J Med Genet.</source>
                <year>1984</year>
                <volume>18</volume>
                <fpage>369</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">6431819</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.hendriksz.2013.309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hendriksz</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Jawad</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>KI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawley</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawrence</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mc Ardle</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Summers</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wright</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braunlin</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2013</year>
                <volume>36</volume>
                <fpage>309</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">22358740</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.higaki.2011.843">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Higaki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bahrudin</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okuzawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takamuram</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adachi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paraguison</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikehata</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tominaga</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hisatome</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iida</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuda</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ninomiya</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakakibara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohno</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nanba</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in &#x003b2;-galactosidase deficiency.</article-title>
                <source>Hum Mutat.</source>
                <volume>32</volume>
                <fpage>843</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">21520340</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.hofer.2010.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hofer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fantur</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roubergue</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vellodi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poorthuis</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michelakakis</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pashke</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Phenotype determining alleles in GM1 gangliosiosis patients bearing novel GLB1 mutations.</article-title>
                <source>Clin Genet.</source>
                <volume>78</volume>
                <fpage>236</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">20175788</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.kornberg.2000.191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kornberg</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Anti-GM1 ganglioside antibodies: their role in the diagnosis and pathogenesis of immune-mediated motor neuropathies.</article-title>
                <source>J Clin Neurosci.</source>
                <volume>7</volume>
                <fpage>191</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10833614</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.monta_o.2007.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monta&#x000f1;o</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomatsu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gottesman</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orii</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>International Morquio A registry: Clinical manifestation and natural course of Morquio A disease.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>30</volume>
                <fpage>165</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">17347914</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.monta_o.2008.1286">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monta&#x000f1;o</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomatsu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brusius</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orii</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Growth charts for patients affected with Morquio A disease.</article-title>
                <source>Am J Med Genet</source>
                <volume>146A</volume>
                <fpage>1286</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">18412124</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.morgan.2002.641">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rehman</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Morquio's syndrome and its anaesthetic considerations.</article-title>
                <source>Paediatr Anaesth.</source>
                <volume>12</volume>
                <fpage>641</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12358664</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.morreau.1989.20655">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morreau</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galjart</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillemans</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Horst</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d'Azzo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Alternative splicing of beta-galactosidase mRNA generates the classic lysosomal enzyme and a beta-galactosidase-related protein.</article-title>
                <source>J Biol Chem.</source>
                <volume>264</volume>
                <fpage>20655</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">2511208</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.muhlebach.2011.133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Muhlebach</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wooten</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muenzer</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Respiratory manifestations in mucopolysaccharidoses.</article-title>
                <source>Paediatr Respir Rev.</source>
                <volume>12</volume>
                <fpage>133</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21458742</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.neufeld.2001">
              <mixed-citation publication-type="book">Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease.</italic> McGraw-Hill; 2001:3421-52.</mixed-citation>
            </ref>
            <ref id="gm1-ganglio.REF.ohto.2012.1801">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ohto</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Usui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Satow</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Crystal structure of human &#x000df;-galactosidase: structural basis of GM1 gangliosidosis and Morquio B diseases.</article-title>
                <source>J Biol Chem.</source>
                <volume>287</volume>
                <fpage>1801</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">22128166</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.privitera.1998.6319">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Privitera</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prody</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Callahan</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hinek</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>The 67-kDa enzymatically inactive alternatively spliced variant of beta-galactosidase is identical to the elastin/laminin-binding protein.</article-title>
                <source>J Biol Chem.</source>
                <volume>273</volume>
                <fpage>6319</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">9497360</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.rodriguez.2010.679">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackenzie</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ditro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chidekel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaffer</surname>
                    <given-names>TH</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Skeletal dysplasias: evaluation with impulse oscillometry and thoracoabdominal motion analysis.</article-title>
                <source>Pediatr Pulmonol.</source>
                <volume>45</volume>
                <fpage>679</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">20575094</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.roze.2005.1366">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roze</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopez</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eck</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maurel-Ollivier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doummar</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caillaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galanaud</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Billette de Villemeur</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidailhet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roubergue</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Dystonia and parkinsonism in GM1 type 3 gangliosidosis.</article-title>
                <source>Mov Disord.</source>
                <volume>20</volume>
                <fpage>1366</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15986423</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.santamaria.2007.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Santamaria</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chab&#x000e1;s</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grinberg</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilageliu</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Identification of 14 novel GLB1 mutations, including five deletions, in 19 patients with GM1 gangliosidosis from South America.</article-title>
                <source>Clin Genet.</source>
                <volume>71</volume>
                <fpage>273</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17309651</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.shapiro.2006.875">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hatters-Friedman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandes-Filho</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anthony</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Natowicz</surname>
                    <given-names>MR</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Late-onset Tay-Sachs disease: adverse effects of medications and implications for treatment.</article-title>
                <source>Neurology</source>
                <volume>67</volume>
                <fpage>875</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16966555</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.shield.2005.797">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shield</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steward</surname>
                    <given-names>CG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Bone marrow transplantation correcting beta-galactosidase activity does not influence neurological outcome in juvenile GM1-gangliosidosis.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>28</volume>
                <fpage>797</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16151914</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.solanki.2013.339">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Solanki</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theroux</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lampe</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shediac</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lampe</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackenzie</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendriksz</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harmatz</surname>
                    <given-names>PR</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome):presentation, diagnosis and management.</article-title>
                <source>J. Inherit Metab Dis.</source>
                <volume>36</volume>
                <fpage>339</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">23385297</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.sperb.2013.113">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sperb</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vairo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayer</surname>
                    <given-names>FQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matte</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giugliani</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Genotypic and phenotypic characterization of Brazilian patients with GM1 gangliosidosis.</article-title>
                <source>Gene.</source>
                <volume>512</volume>
                <fpage>113</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">23046582</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.steenweg.2010.2971">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steenweg</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanderver</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blaser</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bizzi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Koning</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Wieringen</surname>
                    <given-names>WN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barkhof</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>NI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Magnetic resonance imaging pattern recognition in hypomyelinating disorders.</article-title>
                <source>Brain</source>
                <volume>133</volume>
                <fpage>2971</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">20881161</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.suzuki.2014">
              <mixed-citation publication-type="web">Suzuki Y, Nanba E, Matsuda J, Higaki K, Oshima A. &#x003b2;-galactosidase deficiency (&#x003b2;-galactosidosis): GM1 gangliosidosis and Morquio B disease. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> Chap 151. New York, NY: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>. 2014.</mixed-citation>
            </ref>
            <ref id="gm1-ganglio.REF.takai.2013.526">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higaki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguilar-Moncayo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mena-Barrag&#x000e1;n</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ninomiya</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Moreno</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakakibara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohno</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nanba</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ortiz Mellet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a Fern&#x000e1;ndez</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.</article-title>
                <source>Mol Ther.</source>
                <volume>21</volume>
                <fpage>526</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">23337983</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.tomatsu.2011.931">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tomatsu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monta&#x000f1;o</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oikawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barrera</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinen</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thacker</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackenzie</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orii</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment.</article-title>
                <source>Curr Pharm Biotechnol.</source>
                <volume>12</volume>
                <fpage>931</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">21506915</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.van_der_spoel.2000.10035">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van der Spoel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonten</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d'Azzo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Processing of lysosomal beta-galactosidase. The C-terminal precursor fragment is an essential domain of the mature enzyme.</article-title>
                <source>J Biol Chem.</source>
                <year>2000</year>
                <volume>275</volume>
                <fpage>10035</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">10744681</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.walker.2013.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belani</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braunlin</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruce</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hack</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harmatz</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rowe</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solanki</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valdemarsson</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Anaesthesia and airway management in mucopolysaccharidosis.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>36</volume>
                <fpage>211</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23197104</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.wilson.2007.739">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taubert</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gewitz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lockhart</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baddour</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levison</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolger</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabell</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baltimore</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newburger</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tani</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerber</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonow</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pallasch</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shulman</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rowley</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burns</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrieri</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goff</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durack</surname>
                    <given-names>DT</given-names>
                  </name>
                  <collab>American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young</collab>
                </person-group>
                <article-title>Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group; American Dental Association. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.</article-title>
                <source>J Am Dent Assoc.</source>
                <year>2007</year>
                <volume>138</volume>
                <fpage>739</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">17545263</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.wood.2013.293">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harvey</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burin</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chien</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Church</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Almeida</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Diggelen</surname>
                    <given-names>OP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fietz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giugliani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harmatz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawley</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ketteridge</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukacs</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasquali</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schenone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tylee</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendriksz</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Diagnosing mucopolysaccharidosis IVA.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>36</volume>
                <fpage>293</fpage>
                <lpage>307</lpage>
                <pub-id pub-id-type="pmid">23371450</pub-id>
              </element-citation>
            </ref>
            <ref id="gm1-ganglio.REF.wraith.1995.263">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wraith</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <article-title>The mucopolysaccharidoses: a clinical review and guide to management.</article-title>
                <source>Arch Dis Child.</source>
                <year>1995</year>
                <volume>72</volume>
                <fpage>263</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">7741581</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="gm1-ganglio.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="gm1-ganglio.Suggested_Reading.reflist0">
            <ref id="gm1-ganglio.REF.norman.1959.409">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Norman</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urich</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tingey</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodbody</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>1959</year>
                <article-title>Tay-Sachs&#x02019; disease with visceral involvement and its relationship to Niemman-Pick disease.</article-title>
                <source>J Pathol Bacteriol.</source>
                <volume>78</volume>
                <fpage>409</fpage>
                <pub-id pub-id-type="pmid">14427628</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="gm1-ganglio.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="gm1-ganglio.Author_Notes">
          <title>Author Notes</title>
          <p>The Medical Genetics Branch of the National Human Genome Research Institute continues to study the natural history of patients with GM1. Careful phenotyping and advanced imaging facilitate the characterization of disease progression necessary to evaluate the efficacy of therapeutic interventions. The laboratory is also engaged in studying biomarkers of disease progression in clinical samples, particularly CSF. Careful, repeated observations especially in later-onset patients have identified significantly decreased bone density and an increased incidence of odontoid hypoplasia, particularly in juvenile patients [Author, unpublished observations]. These findings may impact surgical decision making and the activities of daily living.</p>
        </sec>
        <sec id="gm1-ganglio.Acknowledgments">
          <title>Acknowledgments</title>
          <p>Dr. Alessandra d&#x02019;Azzo provided editorial comments and important insights included in this <italic toggle="yes">GeneReview</italic>.</p>
          <p>Dr. J&#x000fc;rgen Spranger is instrumental in the current natural history studies being conducted at the National Human Genome Research Institute at the National Institutes of Health. His findings regarding odontoid hypoplasia are included in the current studies section of this <italic toggle="yes">GeneReview</italic>.</p>
        </sec>
        <sec id="gm1-ganglio.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>17 October 2013 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>24 January 2013 (ct) Original submission</p>
            </list-item>
          </list>
          <p>Note: Pursuant to 17 USC Section 105 of the United States Copyright Act, the <italic toggle="yes">GeneReview</italic> &#x02018;<italic toggle="yes">GLB1</italic>-Related Disorders&#x02019; is in the public domain in the United States of America.</p>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="gm1-ganglio.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Image obtained with a slit lamp demonstrating mild to moderate corneal clouding in an adolescent with the juvenile form of GM1 gangliosidosisPicture courtesy of Dr. Wahdi Zein, National Eye Institute, National Institutes of Health, Bethesda, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gm1-ganglio-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="gm1-ganglio.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Radiographs of the late infantile form of GM1 gangliosidosisA. The odontoid process is under ossified (white arrow). The vertebral bodies are flattened (black arrow). B. Hip x-rays showing dysostosis multiplex. The infero-lateral portions of the ilia are not formed, leading to slanting of their lower margins (gray bracket). The capital femoral epiphyses are well-rounded, slightly larger and shorter than normal, and in valgus position (white bracket). C. The vertebral bodies are more severely flattened dorsally than anteriorly (white arrow) and pear-shaped (black arrow). Defective ossification of the anterior portions of the vertebral bodies in the thoraco-lumbar junction results in a hook shape (black arrow).</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gm1-ganglio-Image002" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="gm1-ganglio.F3" orientation="portrait">
          <label>Figure 3. </label>
          <caption>
            <p>Brain MRI findings in a child with the late infantile form of GM1 gangliosidosisA. At age 3 years 6 months: T<sub>2</sub>-weighted axial view showing minimal atrophyB and C. At age 6 years 10 months: T<sub>2</sub>-weighted axial view showing progressive atrophy as evidenced by enlarged ventricles (black arrows) and T<sub>2</sub>-weighted axial view showing extensive brain iron accumulation within the globus pallidus (white arrows).</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gm1-ganglio-Image003" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
